BeiGene | Study of Tislelizumab in Combination With Chemotherapy Compared to Chemotherapy Alone for Participants With Urothelial Carcinoma

⟵ Back to Search Results

Study of Tislelizumab in Combination With Chemotherapy Compared to Chemotherapy Alone for Participants With Urothelial Carcinoma

Beigene Study ID

BGB-A317-310

ClinicalTrials.gov ID

NCT03967977

China Drug Trials ID

CTR20190543

Study Overview

Sex: All

Age: 18 Years / 75 Years

No Study Documents

Locations

Study Overview

Sex: All

Age: 18 Years / 75 Years

No Study Documents